NARA Discovery
Article Details
← Back to Search Results
Journal Article

Osteogenically-induced exosomes stimulate osteogenesis of human adipose-derived stem cells

Mengru Zhu; Yang Liu; Hongzhi Qin; Shuang Tong; Qiang Sun; Ting Wang; Hua Zhang; Mengying Cui; Shu Guo
Cell and Tissue Banking · Vol. 22, Issue 1 · pp. 77-91 · 2021

Abstract

Exosomes exhibit great therapeutic potential in bone tissue engineering. The study aimed to investigate whether the exosomes derived from human adipose-derived stem cells (hADSCs-Exos) during different time-span of osteogenic differentiation could promote osteogenesis. The appropriate concentrations of hADSCs-Exos to enhance the proliferation, migration and osteogenesis of hADSCs-Exos were also examined. PKH67 labelled hADSCs-Exos was used to detect the internalization ability of hADSCs. The osteogenic differentiation abilities of hADSCs after treatment with hADSCs-Exos was evaluated by Alizarin red staining (ARS). The proliferation and migration of hADSCs was examined by cell counting kit-8 and wound healing assay, respectively. The expression of exosomal surface markers and osteoblast-related protein of hADSCs was assessed by Western blot. PKH67-labelled exosomes were internalized by hADSCs after 4 h incubation. ARS showed that the amount of mineralized nodules in Exo 1−14d group was significantly higher than that in Exo 15−28d group. hADSCs-Exos could promote the proliferation and migration capacity of hADSCs. Western blot analysis showed that after hADSCs-Exos treatment, ALP and RUNX2 were significantly enhanced. Specially, the Exo 1−14d group of 15 μg/mL significantly upregulated the expression of RUNX2 than the other exosomes treated groups. Our findings suggest that exosomes secreted by hADSCs during osteogenic induction for 1–14 days could be efficiently internalized by hADSCs and could induce osteogenic differentiation of hADSCs. Moreover, administration of Exo 1−14d at 15 μg/mL promoted the proliferation and migration of hADSCs. In conclusion, our research confirmed that comprised of hADSCs-Exos and hADSCs may provide a new therapeutic paradigm for bone tissue engineering.

Bibliographic Information

JournalCell and Tissue Banking
PublisherSpringer
Publication Date2021-03-01
Publication Year2021
Volume22
Issue1
Pages77-91
Document TypeJournal Article
eISSN1573-6814
DOI10.1007/s10561-020-09867-8

Access Information

NARA Access Coverage2000-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10561
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.